Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA - Chemoablation for Low Grade Bladder Cancer
2024-517106-28-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Gemmis in bladder cancer, sponsored by Medical University of Vienna. Primary endpoint: Clinical complete response. Planned start Oct 2024; status: authorised.
02
Drugs
Gemmis
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2024-517106-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517106-28-00.